Biophytis

Biotechnology ResearchÎle-de-france, France11-50 Employees

Biophytis SA is a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging.

Our small molecules are aimed at stimulating biological resilience to stress during aging.

Ruvembri - in regulatory and clinical phases - is our leading drug candidate is administered orally:

• for the treatment of severe respiratory events related to COVID-19 following positive results in Phase 2/3 clinical study (COVA)
• for the treatment of reduced mobility in elderly patients with sarcopenia, with promising results in a Phase 2 clinical study (SARA) conducted in the United States and Europe


A pediatric formulation of Ruvembri is being developed with IND granted in the US and Belgium (MYODA) for the treatment of Duchenne Muscular Dystrophy (DMD).

Sign up for free to view info

Email Format Employee directory